Poseida Therapeutics (NASDAQ:PSTX) Price Target Lowered to $14.00 at Cantor Fitzgerald

Posted by on Aug 9th, 2023

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) had its target price lowered by research analysts at Cantor Fitzgerald from $17.00 to $14.00 in a research note issued to investors on Wednesday, FlyOnTheWall reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Poseida Therapeutics in a report on Tuesday.

View Our Latest Report on PSTX

Poseida Therapeutics Price Performance

NASDAQ PSTX opened at $1.98 on Wednesday. The company has a market cap of $171.82 million, a PE ratio of -3.25 and a beta of 0.12. Poseida Therapeutics has a 52 week low of $1.54 and a 52 week high of $8.82. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.37. The firm’s 50-day simple moving average is $2.03 and its two-hundred day simple moving average is $3.60.

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The business had revenue of $10.34 million for the quarter, compared to analysts’ expectations of $10.00 million. Poseida Therapeutics had a negative net margin of 32.13% and a negative return on equity of 28.56%. Research analysts predict that Poseida Therapeutics will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Poseida Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its stake in Poseida Therapeutics by 984.9% in the fourth quarter. Millennium Management LLC now owns 1,646,897 shares of the company’s stock valued at $8,729,000 after purchasing an additional 1,495,099 shares in the last quarter. Vanguard Group Inc. raised its stake in Poseida Therapeutics by 79.9% in the third quarter. Vanguard Group Inc. now owns 2,384,866 shares of the company’s stock valued at $8,419,000 after purchasing an additional 1,059,216 shares in the last quarter. Acadian Asset Management LLC raised its stake in Poseida Therapeutics by 406.8% in the first quarter. Acadian Asset Management LLC now owns 1,011,383 shares of the company’s stock valued at $3,115,000 after purchasing an additional 811,819 shares in the last quarter. Marshall Wace LLP purchased a new stake in Poseida Therapeutics in the fourth quarter valued at approximately $2,710,000. Finally, Dimensional Fund Advisors LP raised its stake in Poseida Therapeutics by 172.8% in the first quarter. Dimensional Fund Advisors LP now owns 754,125 shares of the company’s stock valued at $2,323,000 after purchasing an additional 477,706 shares in the last quarter. 50.79% of the stock is owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

(Get Free Report)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

See Also

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.